IL1B and gout: Recently, randomized controlled trials found that two anti-IL-1β biologic agents (rilonacept and canakinumab) prevented gouty arthritis during the initiation of urate-lowering therapy with allopurinol [10,11], but only canakinumab demonstrated efficacy for acute gouty arthritis [9,12].